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The distinct ATP-dependent ransporters for taurocholate, leukotriene C4, and daunorubicin, studied in rat liver canalicular membrane vesicles, 
are sensitive to inhibition by cyclosporin A and its non-immunosuppressive analog PSC 833. K, values for cyclosporin A were 0.2,3.4 and 1.5pM 
for the transport of taurocholate, leukotriene C4, and daunorubicin, respectively. The corresponding X; values for PSC 833 were 0.6, 29, and 0.3 
PM. Both inhibitors were competitive with respect o the three substrates. The cyclosporins erve as new and potent tools to interfere with different 
potency with the distinct ATP-dependent export carriers in the hepatocyte canalicular membrane. 
ATP-dependent ransport; Daunorubicin; LTCq Multidrug resistance; P-glycoprotein; Taurocholate 
1. INTRODUCTION 
Primary-active ATP-dependent ransport is the major 
mechanism to secrete toxic and non-toxic, exo- 
genous as well as endogenous substances across the 
hepatocyte canalicular membrane into bile [l]. Three 
distinct ATP-dependent carriers were so far described 
in this membrane domain. (i) The ATP-driven bile salt 
export carrier (BSEC), discovered in 1991, is now con- 
sidered to be predominantly responsible for the secretion 
of bile salts across the canalicular membrane [2-51. (ii) 
The ATP-dependent leukotriene export carrier (LTEC) 
secretes conjugates of various exogenous and en- 
dogenous substances, uch as the cysteinyl eukotrienes, 
with glutathione, glucuronide, or sulfate moieties [ 1,6]. 
(iii) The ATP-dependent daunorubicin transport medi- 
ated by P-glycoprotein was established in analogy to its 
function in multidrug-resistant tumor cells, although 
endogenous ubstrates for this export carrier still await 
identification [7,8]. The ATP-dependent daunorubicin 
transport in liver showed characteristic properties of a 
P-glycoprotein-mediated transport including inhibition 
by verapamil [8]. In contrast, BSEC and LTEC are not 
inhibited by typical P-glycoprotein substrates [2,6]. The 
only common inhibitor of these P-type ATPases de- 
scribed previously has been vanadate [2-81. 
tidrug resistance (MDR) phenotype in tumor cells ex- 
pressing high levels of the mdrl gene product P- 
glycoprotein [9]. In vitro studies using isolated plasma 
membrane vesicles from multidrug resistant carcinoma 
cell lines have shown that CsA is a strong inhibitor of 
P-glycoprotein-mediated, ATP-driven vinblastine 
transport [lo]. In cytotoxicity assays and in vivo studies 
in mice, CsA and its analog PSC 833 were capable to 
overcome the resistance of P-glycoprotein-expressing 
cells and implanted tumors to a variety of chemother- 
apeutic agents [11,121. In human serum levels of 24 ,uM 
CsA prolonged the elimination half-life of the co-ad- 
ministered chemotherapeutic drug more than two times 
[13]. A possible explanation is that cyclosporins do not 
only mediate an enhanced accumulation of the co-ad- 
ministered drug in tumor cells, but also delay the drug 
elimination into bile, possibly by inhibiting P-glycopro- 
tein-mediated transport in the liver [13]. We present 
evidence that this observation is based on the potent 
inhibition of ATP-dependent daunorubicin transport in 
the hepatocyte canalicular membrane. 
Cyclosporin A (CsA) and its non-immunosuppressive 
analog PSC 833 are potent drugs to reverse the mul- 
*Corresponding author. Fax: (49) (6221) 42-2402. 
This study defines the type and extent of inhibition 
by cyclosporins of the different ATP-dependent trans- 
porters using highly enriched rat hepatocyte canalicular 
membrane vesicles. These data provide information on 
possible side effects during cyclosporin therapy either 
for immunosuppression or drug resistance modifica- 
tion. In addition, cyclosporins appear as new and po- 
tent tools for inhibition of different ATP-dependent ex- 
port carriers. 
Abbreviations: BSEC, bile salt export carrier; CsA, cyclosporin A; 
I&,, concentration required for 50% inhibition; LTEC, leukotriene 
export carrier; MDEC, multidrug export carrier; MDR, multidrug 
resistance; SDZ PSC 833 or PSC 833, (3’-oxo4butenyl4methyl- thre- 
oninel)-(Vale)-cyclosporin; TC, taurocholate; LTC4, leukotriene C4. 
2. MATERIALS AND METHODS 
2.1. Chemicals and inhibitors 
ATP (potassium salt), 5’-AMP (free acid), creatine phosphate (Tris 
salt), unlabeled taurocholate, and daunorubicin were purchased from 
Published by Elsevier Science Publishers B. F 193 
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Sigma Chemical Co., St. Louis, MO, USA. Creatine kinase and re- 
duced glutathione were obtained from Boehringer-Mannheim, 
Mannheim, Germany. Unlabeled LTC4 was from Amersham-Buch- 
ler, Braunschweig, Germany. [y-‘H]Daunorubicin (59 GBq/mmol), 
[y-3H]taurocholate (74 GBq/mmol), and [14,15,19,2&‘H]LTC4 (4700 
GBq/mmol) were from DuPont-New England Nuclear, Boston, MA, 
USA. Nitrocellulose filters (pore size 0.2 ,um) were from Schleicher & 
Schiill, Dassel, Germany. Nick spin columns filled with Sephadex 
G-SO fine were purchased from Pharmacia-LKB, Freiburg, Germany. 
Scintillation fluids (Filter Count and Ultima Gold) were from Can- 
berra Packard, Warrenville, IL, USA. All other chemicals were of 
analytical grade. CsA and PSC 833, kindly provided by Sandoz AG, 
Basel, Switzerland, were prepared as 10 mM stock solutions in 100% 
ethanol and stored at -20°C. Both were diluted to their final concen- 
tration in 250 mM sucrose and 10 mM HEPES/Tris (pH 7.4), so that 
the final ethanol concentration ever exceeded 0.5%. In control exper- 
iments without CsA or PSC 833 a corresponding concentration of 
ethanol was added to the medium in order to control any effects of 
the solvent. 
2.2. Animals 
For preparations enriched in liver canalicular membranes, male 
Wistar rats (200-250 g) were obtained from the Zentralinstitut fiir 
Versuchstierzucht, Hannover, Germany. Animals were maintained on 
a standard diet with free access to food and water. 
2.3. Preparation and characterization of membranes 
Liver membrane fractions enriched in the hepatocyte canalicular 
domain were prepared and characterized as described 121. 
2.4. Measurement of ATP-dependent taurocholate transport into in- 
side-out canalicular membrane vesicles 
Transport of [‘H]TC into the vesicles [2,6] xas measured as follows: 
membrane vesicles (30 pg of protein) were incubated in the presence 
of 4 mM ATP, 10 mM MgCl,, 10 mM creatine phosphate, 100 &ml 
creatine kinase, and the labeled substrate in 250 mM sucrose and 10 
mM HEPEYTris (pH 7.4) at a final volume of 110 ~1. Potassium or 
Tris salts instead of sodium salts of the medium components were used 
throughout. 20-~1 samples were taken at the indicated time points and 
diluted in 1 ml of ice-cold 250 mM sucrose and 10 mM HEPES/Tris 
(pH 7.4). The samples were applied to nitrocellulose filters (0.2 ,um 
pore size) pre-soaked in 250 mM sucrose and 10 mM HEPES/Tris (pH 
7.4). Uptake of rH]TC was measured by a rapid filtration technique 
[2-61. The nitrocellulose filters were rinsed with 5 ml of 1 mM unla- 
beled TC, 250 mM sucrose, 10 mM HEPESlTris (pH 7.4) and 5 ml 
of 250 mM sucrose, 10 mM HEPES/Tris @H 7.4). In control experi- 
ments ATP was replaced by 5’-AMP. Vesicle-associated radioactivity 
retained on the filters was assessed by liquid scintillation counting. 
Transport rates were calculated by subtracting the values in the pres- 
ence of 5’-AMP from the ones in the presence of ATP. 
2.5. Measurement of ATP-dependent LTC4 transport into canalicular 
membrane vesicles 
[‘H]LTC4 transport was essentially determined as described above 
for [‘H]TC transport. Reduced glutathione was added to the incuba- 
tion at a final concentration of 5 mM to prevent binding of LTC4 to 
the membrane-bound glutathione S-transferase and degradation of 
LTC4 to LTD4 by the canalicular membrane y-glutamyltransferase. 
2.6. Measurement of ATP-dependent daunorubicin transport into ca- 
nalicular membrane vesicles 
The incubation to measure daunorubicin transport into canalicular 
membrane vesicles was similar as described above for the other sub- 
strates. The rapid filtration method with nitrocellulose filters was 
replaced, however, by centrifugation of the vesicles through a gel 
matrix. Nick spin columns (1 g Sephadex G-50/2 ml) were prepared 
by rinsing with 1 mM unlabeled TC, 250 mM sucrose, 10 mM HEPESl 
Tris (pH 7.4), and centrifuged at 400 x g and 4°C for 4 min before use. 
The incubation medium was composed of the same ATP-regenerating 
system as for TC transport in a final volume of 110 ~1. 2O;ul samples 
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of the incubation medium were diluted in 80 ~1 of ice-cold 250 mM 
sucrose, 10 mM HEPES/Tris (pH 7.4) and loaded on the Sephadex 
G-50 column. The columns were rinsed with 100 ~1 of 250 mM su- 
crose, 10 mM HEPES/Tris (pH 7.4) and centrifuged at 400 x g and 
4°C for 4 min as described [14,15]. The ef3uent was collected and 
assayed for the radioactivity associated with the vesicles. 
3. RESULTS 
3.1. Kinetic characterization of the inhibition by cy- 
closporins of the primary-active transport of tauro- 
cholate, leukotriene C,, and daunorubicin 
CsA and PSC 833 both inhibited the ATP-dependent 
TC transport efficiently with IC50 values of 1 PM (Figs. 
1 and 2). The concentrations of CsA and PSC 833 nec- 
essary to induce 50% inhibition of ATP-dependent 
LTC4 transport were 6-times and 15-times higher, re- 
spectively, than the ones required to inhibit TC trans- 
port by 50% (Figs. 1 and 2). ATP-driven daunorubicin 
transport exhibited a marked discrepancy between the 
inhibitory potency of CsA and PSC 833, i.e. a 5-times 
less potent inhibition by CsA as compared to PSC 833 
(Figs. 1 and 2). 
Kinetic analyses indicated a competitive inhibition by 
both CsA and PSC 833 of LTC4 as well as daunorubicin 
transport (Figs. 3 and 4). TC transport was also com- 
petitively inhibited by PSC 833 (graph not shown), 
which corresponds to our report on inhibition of ATP- 
dependent TC transport by CsA [16]. The Ki values for 
TC transport were similar for CsA and PSC 833 (Table 
I). The corresponding Ki values for inhibition of LTC4 
transport showed the largest difference of inhibition 
between the two cyclosporins (Fig. 3). The Ki values for 
daunorubicin transport indicated a 5-fold difference of 
transport inhibition by the two cyclosporins (Fig. 4). 
3.2. Comparison of substrate and inhibitor ef$ciency of 
the three transporters in the canalicular membrane 
The LTEC showed the lowest K, value of the three 
CsA (IJM) 
Fig. 1. Inhibition by CsA of ATP-dependent ransport of TC, LTC4, 
and daunorubicin into isolated rat canalicular membrane vesicles. 
Membrane vesicles were incubated in the presence of ATP, MgCl,, 
creatine phosphate, creatine kinase, and the respective substrate for 
1 min. In the blank assays ATP was replaced by 5’-AMP. The concen- 
trations of TC, LTC4, and daunorubicin were 5 PM, 50 nM, and 5 
PM, respectively. Each point represents the mean from 4 separate 
measurements. 
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Fig. 2. Inhibition by PSC 833 of ATP-dependent ransport of TC, 
LTC4. and daunorubicin into isolated canalicular membrane vesicles. 
Incubation conditions were the same as described in the legend to Fig. 
1. Each point represents the mean from 4 separate measurements. 
carriers with 0.32 ~.LM for LTC4 followed by the BSEC 
with a X, value of 10 ,uM for TC. The MDEC displayed 
the highest K, value of 20 ,LJM as measured with daun- 
orubicin, in the absence of a known endogenous ub- 
strate (Table II). Calculation of the Y,J&, ratios for 
the transporters, which provides information on the ef- 
ficiency of a transporter with a given substrate, leaves 
the BSEC and LTEC as the most efficient with ratios 
of 180 and 425, respectively, compared to MDEC with 
a ratio of only 14 (Table II). 
The efficiency of the cyclosporins as inhibitors in the 
presence of a given substrate was calculated by the K,,,/ 
Ki ratio (Table I). The most conspicuous result was the 
limited effect of the two cyclosporins on the LTEC 
(ratio 0.09 and 0.01 for CsA and PSC 833, respectively), 
while the ratio for CsA is similar for the BSEC and 
MDEC (25 and 13, respectively). PSC 833 achieves the 
highest inhibitor efficiency on the MDEC (ratio 67) 
compared to the BSEC (ratio 17; Table II). 
4. DISCUSSION 
4.1. Differential inhibition of the primary-active trans- 
porters for taurocholate, LTC,, and daunorubicin 
The distinct ATP-dependent transporters for the 
physiological substrates TC [2-51 and LTC4 [6], and for 
the chemotherapeutic drug daunorubicin [83 in the 
hepatocyte canalicular membrane exhibit different sus- 
ceptibility to inhibition by two cyclosporins which difXer 
in their immunosuppressive action. PSC 833 was a more 
potent inhibitor of multidrug transport than CsA. ATP- 
dependent TC transport was equally a&&xl by CsA and 
PSC 833. Though the Ki values for inhibition of TC and 
daunorubicin transport by PSC 833 are similar, the in- 
hibitor efficiency, estimated from the &JK ratios, re- 
vealed the 4-fold stronger influence on daunorubicin 
transport (Table I). Daunorubicin transport showed a 
low substrate efficiency ratio, which may be due to the 
fact that it is an unphysiologic exogenous ubstrate for 
this transporter. 
Table I 
X; values for CsA and PSC 833 and inhibitor efficiency relative to the 
substrate 
Substrate for ATP- 
dependent ransport 
K KJlui 
CsA PSC CsA PSC 
NM) 
Taurocholate 0.2 0.6 50 17 
LTC, 3.4 29 0.09 0.01 
Daunorubicin 1.5 0.3 13 61 
The concentration of TC ranged from 1 PM to 20 /IM, from 25 nM 
to 500 nM for LTC4, and from 1 PM to 10 PM for daunorubicin. 
Transport studies were performed as described in section 2. K, values 
were determined by the Lineweaver-Burk equation for competitive 
inhibition. Values are from quadrupli~te dete~inations with all 
standard deviations at less than 15% of the mean. 
The non-immunosuppressive CsA derivative PSC 833 
is modified in only 3 positions [ 11,121. At the first amino 
acid CsA (~-methyl-4-butenyl-4-methyl-threonine) the
~-methyl group is removed and the hydroxyl group at 
carbon atom 3 is oxidized to an 0x0 group. The second 
amino acid (L-2-amino-butyrate) is replaced by valine, 
resulting in an additional methyl group. These modifi- 
cations lead to a loss of immunosuppressive properties 
[12]. In our study, we demonstrate that PSC 833 gains 
a higher efficiency to inhibit the ~-gly~oprotein-medi- 
ated daunorubicin transport while losing efficiency to 
0 20 40 60 
Fig. 3. Competitive inhibition by CsA (upper panel) and PSC 833 
(lower panel) of ATP-dependent LTC4 transport. Double reciprocal 
plots according to Lineweaver and Burk in the presence of 5 PM and 
10 PM CsA (upper panel) and 20 PM PSC 833 (lower panel) with 
varying LTC4 concentrations (25-50 nM). Incubation conditions were 
the same as described in the Iegend to Fig. 1. The straight lines were 
calculated by the least squares method. Mean values _+ S.D. from 4 
determinations. 
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Fig. 4. Competitive inhibition by CsA (upper panel) and PSC 833 
(lower panel) of ATP-dependent daunorubicin transport. Double re- 
ciprocal plots in the presence of 3 PM and 5 ,uM CsA (upper panel) 
and 0.5 PM and 1 PM PSC 833 (lower panel) with daunorubicin 
concentrations ranging from 1 to 10 PM. The lines are calculated by 
the least squares method. Mean values + S.D. from 4 determinations. 
inhibit LTC4 transport (Figs. 1 and 2). The results dem- 
onstrate how cyclosporin derivatives may be used as 
molecular tools to characterize transport processes in 
an in vitro membrane vesicle transport system. Espe- 
cially CsA and PSC 833 in combination provide a 
means to distinguish between transporters by their in- 
hibitor efficiency. 
4.2. Pathophysiological implications 
Inhibition of the ATP-dependent ransport of organic 
compounds may have several pathophysiological impli- 
cations: (i) cholestasis indicated by a rise in serum bile 
salts and bilirubin is a well known side effect of im- 
munosuppressive CsA therapy after successful organ 
transplantation [17,18]. Since CsA and PSC 833 
strongly inhibit the BSEC, it is likely that inhibition of 
the ATP-dependent bile salt transporter in liver is the 
underlying molecular mechanism. (ii) Inhibition of pri- 
mary-active ATP-dependent daunorubicin transport 
may not only serve in the modification of multidrug 
resistance, but also as a mechanism to delay the elimina- 
tion of active drugs from the organism by the liver [13]. 
(iii) Members of the ATP-binding cassette superfamily 
[19,20] other than P-glycoprotein may also be targets 
for inhibition by cyclosporins [10,16]. This mechanism 
can be useful to define the function of these transporters 
by in vivo measurements of substance secretion as well 
as in vitro membrane vesicle transport assays. 
Table II 
Kinetic parameters of three distinct transporters in the hepatocyte 
canalicular membrane 
Substrate for ATP- V 
dependent ransport (pmol . rni’ min-‘) @M) (ml . mg-’ min-‘) 
Taurocholate 1800 10 180 
LTC, 136 0.32 425 
Daunorubicin 280 20 14 
The kinetic constants were derived from double reciprocal plots ac- 
cording to Lineweaver and Burk. Transport studies were performed 
as described in section 2. Values are from quadruplicate determina- 
tions with all standard deviations at less than 15% of the mean. 
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